discovered that ARC increased the levels of IL1β in AML cells by activating the NFκB pathway, thereby promoting chemokine generation in MSCs and ultimately resulting in the enhancement of leukemia cell chemoresistance. This evidence concerns the gene NFKB1 and acute myeloid leukemia.